Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics

Available via

WEBINAR

Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics

Tuesday, May 22, 2018

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

Biochemical Pharmacology Discussion Group

The New York Academy of Sciences

 

Over the past few years we have witnessed considerable progress in the field of kinase inhibitors, however there is still no consensus as to which screening methods are best suited to their identification. This symposium will bring together experts in the field of kinase drug discovery to review the landscape, exploring new approaches and technologies driving the advancement of non-classical kinase inhibitor pipeline, and drawing on past lessons to provide insight into the future direction of the field.

Registration

Member
$60
Nonmember Academia, Faculty, etc.
$105
Nonmember Corporate, Other
$160
Nonmember Not for Profit
$105
Nonmember Student, Undergrad, Grad, Fellow
$70
Member Student, Post-Doc, Fellow
$25
Member
$30
Nonmember Academia, Faculty, etc.
$65
Nonmember Corporate, Other
$85
Nonmember Not for Profit
$65
Nonmember Student, Undergrad, Grad, Fellow
$45
Member Student, Post-Doc, Fellow
$15
Deadline:
0
days
left

Scientific Organizing Committee

Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Lynn Abell, PhD, Agios Pharmaceuticals
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Charu Chaudhry, PhD, Bristol-Myers Squibb
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Amy Hart, PhD, Bristol-Myers Squibb
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Ravi Kurumbail, PhD, Pfizer
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Stephen Noell, Pfizer
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Claire Steppan, PhD, Pfizer
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Sonya Dougal, PhD, The New York Academy of Sciences
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Sara Donnelly, PhD, The New York Academy of Sciences

Keynote Speaker

Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Nathanael S. Gray, PhD, Harvard Medical School

Speakers

Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Dustin James Maly , PhD, University of Washington
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Kimberly Cameron, PhD, Pfizer
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Elizabeth Goldsmith, PhD, University of Texas Southwestern Medical Center
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Markus Seeliger, PhD, Stony Brook University School of Medicine
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Steven Wrobleski, PhD, Bristol-Myers Squibb
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
Dorothee Kern, PhD, Brandeis University
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
John Sanders, PhD, Merck

The Biochemical Pharmacology Discussion Group is proudly supported by:

Regeneron

American Chemical Society New York Chapter

Tuesday

May 22, 2018

8:30 AM

Breakfast and Registration

9:00 AM

Introduction and Welcome Remarks

Speakers

Sonya Dougal, PhD
The New York Academy of Sciences
Ravi Kurumbail, PhD
Pfizer

Keynote Address

9:15 AM

New Chemical Biology and Medicinal Approaches for Targeting Kinase Signaling Pathways

Speaker

Nathanael S. Gray, PhD
Harvard Medical School

Session 1: Kinase Signaling, Structure, and Allostery

Session Chairperson
Amy Hart, PhD, Bristol-Myers Squibb
10:00 AM

Conformational Regulation of Protein Kinases

Speaker

Elizabeth Goldsmith, PhD
University of Texas, Southwestern Medical Center
10:30 AM

Networking Coffee Break

11:00 AM

Targeting Conformational Plasticity and Dynamics of Protein Kinases

Speaker

Markus Seeliger, PhD
Stony Brook University School of Medicine
11:30 AM

Ancient Origins of Allosteric Activation in Kinases – Exploitation for Novel Cancer Drugs

Speaker

Dorothee Kern, PhD
Brandeis University
12:00 PM

Data Blitz Talks – 3x5minute talks selected from submitted abstracts

12:15 PM

Networking Lunch and Poster Session

Session 2: Structure and Dynamics underlying Kinase Allostery

Session Chairperson
Stephen Noell, Pfizer
1:30 PM

Structural characterization of nonactive site, TrkA-selective kinase inhibitors

Speaker

John Sanders, PhD
Merck
2:00 PM

Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src

Speaker

Dustin James Maly, PhD
University of Washington
2:30 PM

Networking Coffee Break

Session 3: Kinase Allosteric Modulators: from Bench to Clinic

Session Chairperson
Charu Chaudhry, PhD, Bristol-Myers
3:00 PM

Discovery of allosteric activators of AMPK, a master metabolic regulator

Speaker

Kim Cameron, PhD
Pfizer
3:30 PM

Pseudokinase Domain of the Janus Kinase (JAK) TYK2: A Novel Target for the Treatment of Immune-Mediated Inflammatory Diseases

Speaker

Steven Wrobleski, PhD
Bristol-Myers Squibb
4:00 PM

Panel Discussion: Integrating Approaches to Identify Novel Kinase Inhibitors

Speaker

Moderator: Charu Chaudhry, PhD
Bristol-Myers Squibb
4:45 PM

Closing Remarks

Speaker

Charu Chaudhry, PhD
Bristol-Myers Squibb
5:00 PM

Networking Reception

6:00 PM

Adjourn